Tocilizumab Biosimilar (Jiangsu Pacific-Meinuoke)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTocilizumab Biosimilar (Jiangsu Pacific-Meinuoke)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJiangsu Pacific Minok Biopharmaceutical Co., Ltd.
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu Pacific Minok Biopharmaceutical Co., Ltd.
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A